[The treatment of heart decompensation using angiotensin converting enzyme inhibitors. Pharmaco-economic aspects].
Heart failure is a challenge for modern cardiology, Common, disabling, lethal, this condition represents a major economic burden for Public Health. When patients with heart failure receive an ACE inhibitor in addition to diuretics and digoxin, they have fewer symptoms, are less frequently admitted to hospital and live longer. The currently available pharmaco-economic analyses support the use of ACE inhibitors in heart failure.
Service de Cardiologie, Université de Liège.
H
H
Kulbertus
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000191:economics / Q000627:therapeutic use*; D002316:Cardiotonic Agents / Q000191:economics / Q000627:therapeutic use; D004077:Digoxin / Q000191:economics / Q000627:therapeutic use; D004232:Diuretics / Q000191:economics / Q000627:therapeutic use; D016527:Drug Costs; D017850:Economics, Pharmaceutical; D017048:Health Care Costs; D006333:Heart Failure / Q000188:drug therapy* / Q000191:economics; D006801:Humans; D010343:Patient Admission; D011634:Public Health / Q000191:economics; D015996:Survival Rate
D000806:Angiotensin-Converting Enzyme Inhibitors; D002316:Cardiotonic Agents; D004232:Diuretics; D004077:Digoxin